O

Ondine Biomedical Inc
LSE:OBI

Watchlist Manager
Ondine Biomedical Inc
LSE:OBI
Watchlist
Price: 9.75 GBX Market Closed
Market Cap: 39.4m GBX
OBI
/
Income Statement
/
Cost of Revenue

Ondine Biomedical Inc
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ondine Biomedical Inc
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
O
Ondine Biomedical Inc
LSE:OBI
Cost of Revenue
-CA$500k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Titan Medical Inc
TSX:TMD
Cost of Revenue
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Profound Medical Corp
TSX:PRN
Cost of Revenue
-$3.6m
CAGR 3-Years
2%
CAGR 5-Years
-15%
CAGR 10-Years
N/A
Nanalysis Scientific Corp
XTSX:NSCI
Cost of Revenue
-CA$24.5m
CAGR 3-Years
-108%
CAGR 5-Years
-52%
CAGR 10-Years
N/A
Theralase Technologies Inc
XTSX:TLT
Cost of Revenue
-CA$479.4k
CAGR 3-Years
-1%
CAGR 5-Years
12%
CAGR 10-Years
0%
MedMira Inc
XTSX:MIR
Cost of Revenue
-CA$147.8k
CAGR 3-Years
26%
CAGR 5-Years
-13%
CAGR 10-Years
22%

Ondine Biomedical Inc
Glance View

Market Cap
39.4m GBX
Industry
Health Care

Ondine Biomedical, Inc. operates as a life sciences company that develops photodisinfection-based therapies to address drug-resistant infections. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2021-12-06. The firm is focused on developing products that utilizes its light-activated technology, primarily for the healthcare-associated infection (HAI) market. Photodisinfection provides a spectrum of antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The company offers solution in Steriwave Nasal Decolonization (ND) and SurgENT. Steriwave ND provides a spectrum antimicrobial providing targeted decolonization. SurgENT is a tool for cleaning and irrigating the paranasal sinuses. The intrasinus balloon design directs irrigant circumferentially around the sinus walls, maintaining debridement pressure.

OBI Intrinsic Value
4.73 GBX
Overvaluation 52%
Intrinsic Value
Price
O
What is Intrinsic Value?

See Also

What is Ondine Biomedical Inc's Cost of Revenue?
Cost of Revenue
-500k CAD

Based on the financial report for Dec 31, 2023, Ondine Biomedical Inc's Cost of Revenue amounts to -500k CAD.

What is Ondine Biomedical Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 1Y
-42%

Over the last year, the Cost of Revenue growth was -42%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 243,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.